OPINION Systemic lupus erythematosus clinical trials-an interim analysis

被引：12

作者：

Dall'Era, Maria ^{[1
]}

Wofsy, David ^{[1
]}

机构：

[1] Univ Calif San Francisco, Div Rheumatol, San Francisco, CA 94121 USA

来源：

NATURE REVIEWS RHEUMATOLOGY | 2009年 / 5卷 / 06期

关键词：

PLACEBO-CONTROLLED TRIAL; TERM-FOLLOW-UP; MYCOPHENOLATE-MOFETIL; DISEASE-ACTIVITY; DOUBLE-BLIND; NEPHRITIS; THERAPY; CYCLOPHOSPHAMIDE; PRASTERONE; REMISSION;

D O I：

10.1038/nrrheum.2009.79

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Since the current standards for drug approval were established nearly half a century ago, no drug has been approved for the treatment of systemic lupus erythematosus (SLE). Despite this sobering history, interest in drug development for SLE has heightened in the past few years. this enthusiasm has been fueled in large part by the success of biologic therapy for rheumatoid arthritis and other autoimmune diseases. Unfortunately, despite considerable clinical trial activity, this interest has not yet translated into the discovery of an effective treatment for SLE. this article provides an analysis of the major clinical trials in SLE, and offers an interpretation of the results that could illuminate the path forward.

引用

页码：348 / 351

页数：4

共 20 条

[1]

[Anonymous], A study to evaluate the efficacy and safety of pemigatinib versus chemotherapy in unresectable or metastatic cholangiocarcinoma (FIGHT -302)

[2]

APPEL GB, J AM SOC NE IN PRESS

[3] THERAPY OF LUPUS NEPHRITIS - CONTROLLED TRIAL OF PREDNISONE AND CYTOTOXIC DRUGS [J].

AUSTIN, HA ;

KLIPPEL, JH ;

BALOW, JE ;

LERICHE, NGH ;

STEINBERG, AD ;

PLOTZ, PH ;

DECKER, JL .

NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (10) :614-619

[4] Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis [J].

Chan, TM ;

Li, FK ;

Tang, CSO ;

Wong, RWS ;

Fang, GX ;

Ji, YL ;

Lau, CS ;

Wong, AKM ;

Tong, MKL ;

Chan, KW ;

Lai, KN .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (16) :1156-1162

[5]

Chatham W, 2008, ARTHRITIS RHEUM, V58, pS573

[6] Sequential therapies for proliferative lupus nephritis [J].

Contreras, G ;

Pardo, V ;

Leclercq, B ;

Lenz, O ;

Tozman, E ;

O'Nan, P ;

Roth, D .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (10) :971-980

[7] Cutting edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide [J].

Daikh, DI ;

Wofsy, D .

JOURNAL OF IMMUNOLOGY, 2001, 166 (05) :2913-2916

[8] Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis [J].

Ginzler, EM ;

Dooley, MA ;

Aranow, C ;

Kim, MY ;

Buyon, J ;

Merrill, JT ;

Petri, M ;

Gilkeson, GS ;

Wallace, DJ ;

Weisman, MH ;

Appel, GB .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (21) :2219-2228

[9] Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy - Long-term followup of a cohort of 145 patients participating in randomized controlled studies [J].

Illei, GG ;

Takada, K ;

Parkin, D ;

Austin, HA ;

Crane, M ;

Yarboro, CH ;

Vaughan, EM ;

Kuroiwa, T ;

Danning, CL ;

Pando, J ;

Steinberg, AD ;

Gourley, MF ;

Klippel, JH ;

Balow, JE ;

Boumpas, DT .

ARTHRITIS AND RHEUMATISM, 2002, 46 (04) :995-1002

[10] Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis [J].